JupiteX Get the app
Health & Medicine16 Nov 2026 · about 6 min

Australia’s national medical research body advises conditional use of puberty blockers for transgender children

The brief

Australia’s National Health and Medical Research Council (NHMRC) has advised that puberty suppressants may be used conditionally in gender-affirming care for children. Its interim national clinical practice guidelines follow a year-long review of international evidence. The council rejected the “wait and see” approach proposed by opponents, describing withholding care as something that can affect a young person’s physical and mental health, wellbeing, and ability to function. The guidelines also state that gender incongruence is not a mental health disorder, though some young people experience significant distress known as gender dysphoria. The advice does not make treatment automatic. It says doctors should prioritise the young person’s best interests and wellbeing, respect their autonomy, and decide whether a multidisciplinary team is appropriate on a case-by-case basis. Public consultation on the interim advice is open until 18 January. Full guidelines covering other care, including gender-affirming hormones, are expected in 2028.

01

What advice did Australia’s NHMRC issue about using puberty blockers for transgender and gender-diverse children?

Australia’s National Health and Medical Research Council (NHMRC) has advised that puberty suppressants may be used conditionally in gender-affirming care for children. Its interim national clinical practice guidelines follow a year-long review of international evidence.

The council rejected the “wait and see” approach proposed by opponents, describing withholding care as something that can affect a young person’s physical and mental health, wellbeing, and ability to function. The guidelines also state that gender incongruence is not a mental health disorder, though some young people experience significant distress known as gender dysphoria.

The advice does not make treatment automatic. It says doctors should prioritise the young person’s best interests and wellbeing, respect their autonomy, and decide whether a multidisciplinary team is appropriate on a case-by-case basis. Public consultation on the interim advice is open until 18 January. Full guidelines covering other care, including gender-affirming hormones, are expected in 2028.

02

What does “conditional use” mean, and what should doctors consider when deciding whether a young person receives treatment?

In the NHMRC’s interim advice, “conditional use” means puberty suppressants are recommended in some circumstances, not as a routine treatment for every child. The article does not list a fixed set of eligibility rules. Instead, it describes an individualised approach to care.

The guidelines say doctors should prioritise the young person’s best interests and wellbeing, while respecting their autonomy. They also say that a multidisciplinary team should be determined on a case-by-case basis. The advice does not require a child to be distressed before receiving treatment for gender incongruence. It distinguishes gender incongruence from gender dysphoria, which refers to significant distress that some young people experience.

This approach leaves decisions to clinicians considering each young person’s situation rather than applying one blanket rule. The council also rejects “wait and see” as an alternative that withholds care, noting that this can affect health, wellbeing, and ability to function. The interim advice is open for public consultation until 18 January.

03

What are puberty blockers, and what do they do in the body?

Puberty blockers are a class of drugs used to stop the body producing oestrogen and testosterone, according to the article. Those hormones are involved in the body’s development during puberty. The drugs are also called puberty suppressants in the NHMRC’s interim guidelines.

In gender-affirming care, the intended effect described in the article is to suppress the body’s production of these hormones. The article does not give details about how the medicines act on hormone signals, how quickly they work, or what changes an individual child might experience. It says the NHMRC recommends their conditional use for children in certain circumstances.

The drugs have also been used for other reasons: the article says they have treated conditions such as precocious puberty since the 1970s. Their use in gender-affirming care began in the 1990s. The interim advice does not cover every aspect of treatment; full guidelines, including guidance on gender-affirming hormones, are expected in 2028.

04

How long have puberty blockers been used, and how has their use changed over time?

Puberty blockers have been used to treat children for a variety of conditions since the 1970s. The article gives precocious puberty as one example. These medicines are also used in gender-affirming care, a use that began in the 1990s.

The article describes blockers as drugs that stop the body producing oestrogen and testosterone. Their use has therefore extended from treatment for conditions such as precocious puberty to gender-affirming care for trans and gender-diverse young people. The NHMRC’s interim advice concerns their conditional use for children in this latter setting.

The council’s advice follows a year-long review of international evidence and largely aligns with existing AusPATH standards for doctors. It is interim guidance, not the full national guidelines. Public consultation is open until 18 January, and the complete guidelines are expected in 2028. They will address other areas of care, including gender-affirming hormones.

05

How could the NHMRC’s advice affect access to care in states and territories that have restricted puberty blockers?

The NHMRC’s interim national guidelines advise conditional use of puberty suppressants for children. The article says this advice could put pressure on state and territory governments to consider their positions. It does not say that the guidelines automatically change local rules or guarantee access to treatment.

Queensland and the Northern Territory governments had imposed bans in their public hospitals, prompting the federal government to commission the NHMRC’s review. New Zealand’s government later followed suit with a ban. The NHMRC’s advice rejects “wait and see” as an alternative, saying withholding care can affect a young person’s health, wellbeing, and ability to function.

The advice is still interim, and public consultation is open until 18 January. Governments may consider the recommendations as positions are reviewed, but the article does not report any decision to lift restrictions. Full guidelines addressing other care, including gender-affirming hormones, are expected in 2028.

06

What is the NHMRC, and why did the federal government ask it to review the evidence?

The National Health and Medical Research Council, or NHMRC, is an independent statutory agency funded by the Commonwealth. The article describes it as one of the world’s largest medical research organisations. It developed interim advice on puberty suppressants for children’s gender-affirming care after a review of international evidence.

The federal government commissioned the council last year after Queensland and the Northern Territory governments imposed bans on the treatment in public hospitals. The NHMRC says its interim advice was developed with input from a multidisciplinary gender guideline development committee and supported by a systematic review of evidence. Its recommendations allow conditional use in certain circumstances.

The advice is interim and open for public consultation until 18 January. It largely aligns with the AusPATH Australian Standards of Care for Informed Consent Gender-Affirming Hormone Therapy, which the article describes as Australia’s only existing guidelines for doctors. Full national guidelines, including advice on gender-affirming hormones, are expected in 2028.

07

How do hormones guide the changes of puberty, and how can medicines temporarily pause those changes?

The article defines puberty blockers as drugs used to stop the body producing oestrogen and testosterone. It does not explain how hormones guide puberty or describe the medicines’ biological mechanism. In general medical knowledge, puberty involves signals from the brain that prompt the body to increase production of sex hormones, which contribute to physical changes.

Many puberty blockers act by reducing signals that stimulate the production of sex hormones. With those signals suppressed, the rise in hormone levels and related pubertal changes can be paused while treatment continues. This is a general explanation of the mechanism; the article itself only states that blockers stop the body producing oestrogen and testosterone.

The NHMRC’s interim guidelines advise conditional use for children in gender-affirming care and say decisions should be made with the young person’s wellbeing and autonomy in mind. The article also notes that blockers have been used for precocious puberty since the 1970s and in gender-affirming care since the 1990s. Full guidelines are expected in 2028.

This brief was written by AI from the original reporting and checked by other models. Names, figures and quotes come from the source; read it for full context.

Read more in the JupiteX app

Pulse is free. New stories every 4 hours, each one broken into the questions that explain it.

Or read more news on the web